This page is kept for reference and is not offered to search engines.
Indication
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
In other countries
The same active substances on other registers, the same brand first.
- Oxbryta 500 MG Comprimidos Recubiertos con PeliculaSpain · 500 mg · comprimido recubierto con película · Pfizer Europe Ma EeigSame brand
- OxbrytaCroatiaSame brand
- OxbrytaItaly · Compressa rivestita con film · Pfizer Europe Ma EeigSame brand
- OxbrytaSaudi Arabia · Patheon INCSame brand
- OxbrytaUnited States · 300MG, 500MG · tablet · Global Blood Theraps